154 related articles for article (PubMed ID: 33181752)
41. PET Imaging of Estrogen Receptors Using
Kumar M; Salem K; Jeffery JJ; Fowler AM
Methods Mol Biol; 2022; 2418():129-151. PubMed ID: 35119664
[TBL] [Abstract][Full Text] [Related]
42. Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol.
Peterson LM; Mankoff DA; Lawton T; Yagle K; Schubert EK; Stekhova S; Gown A; Link JM; Tewson T; Krohn KA
J Nucl Med; 2008 Mar; 49(3):367-74. PubMed ID: 18287268
[TBL] [Abstract][Full Text] [Related]
43. Biodistribution of
Iqbal R; Yaqub M; Oprea-Lager DE; Liu Y; Luik AM; Beelen AP; Schuit RC; Windhorst AD; Boellaard R; Menke-van der Houven van Oordt CW
J Nucl Med; 2022 May; 63(5):694-699. PubMed ID: 34446451
[TBL] [Abstract][Full Text] [Related]
44. Simultaneous breast cancer and DLBCL lymphoma - role of PET/CT examination with 18F-FDG and 18F-FES.
Hołody Ł; Kunikowska J; Braziewicz J
Nucl Med Rev Cent East Eur; 2018; 21(2):113-114. PubMed ID: 29956818
[TBL] [Abstract][Full Text] [Related]
45. Assessment of the novel estrogen receptor PET tracer 4-fluoro-11β-methoxy-16α-[(18)F]fluoroestradiol (4FMFES) by PET imaging in a breast cancer murine model.
Paquette M; Phoenix S; Ouellet R; Langlois R; van Lier JE; Turcotte EE; Bénard F; Lecomte R
Mol Imaging Biol; 2013 Oct; 15(5):625-32. PubMed ID: 23619898
[TBL] [Abstract][Full Text] [Related]
46. Comparative breast tumor imaging and comparative in vitro metabolism of 16alpha-[18F]fluoroestradiol-17beta and 16beta-[18F]fluoromoxestrol in isolated hepatocytes.
Jonson SD; Bonasera TA; Dehdashti F; Cristel ME; Katzenellenbogen JA; Welch MJ
Nucl Med Biol; 1999 Jan; 26(1):123-30. PubMed ID: 10096512
[TBL] [Abstract][Full Text] [Related]
47. Breast cancer models to study the expression of estrogen receptors with small animal PET imaging.
Aliaga A; Rousseau JA; Ouellette R; Cadorette J; van Lier JE; Lecomte R; Bénard F
Nucl Med Biol; 2004 Aug; 31(6):761-70. PubMed ID: 15246367
[TBL] [Abstract][Full Text] [Related]
48. Androgen and Estrogen Receptor Imaging in Metastatic Breast Cancer Patients as a Surrogate for Tissue Biopsies.
Venema CM; Mammatas LH; Schröder CP; van Kruchten M; Apollonio G; Glaudemans AWJM; Bongaerts AHH; Hoekstra OS; Verheul HMW; Boven E; van der Vegt B; de Vries EFJ; de Vries EGE; Boellaard R; Menke van der Houven van Oordt CW; Hospers GAP
J Nucl Med; 2017 Dec; 58(12):1906-1912. PubMed ID: 28912144
[TBL] [Abstract][Full Text] [Related]
49. 18F-Fluoroestradiol PET: Current Status and Potential Future Clinical Applications.
Liao GJ; Clark AS; Schubert EK; Mankoff DA
J Nucl Med; 2016 Aug; 57(8):1269-75. PubMed ID: 27307345
[TBL] [Abstract][Full Text] [Related]
50. Comparison of 18F-FES, 18F-FDG, and 18F-FMISO PET Imaging Probes for Early Prediction and Monitoring of Response to Endocrine Therapy in a Mouse Xenograft Model of ER-Positive Breast Cancer.
He S; Wang M; Yang Z; Zhang J; Zhang Y; Luo J; Zhang Y
PLoS One; 2016; 11(7):e0159916. PubMed ID: 27467716
[TBL] [Abstract][Full Text] [Related]
51. Functional images reflect aggressiveness of endometrial carcinoma: estrogen receptor expression combined with 18F-FDG PET.
Tsujikawa T; Yoshida Y; Kudo T; Kiyono Y; Kurokawa T; Kobayashi M; Tsuchida T; Fujibayashi Y; Kotsuji F; Okazawa H
J Nucl Med; 2009 Oct; 50(10):1598-604. PubMed ID: 19759112
[TBL] [Abstract][Full Text] [Related]
52. Uterine tumors: pathophysiologic imaging with 16alpha-[18F]fluoro-17beta-estradiol and 18F fluorodeoxyglucose PET--initial experience.
Tsujikawa T; Yoshida Y; Mori T; Kurokawa T; Fujibayashi Y; Kotsuji F; Okazawa H
Radiology; 2008 Aug; 248(2):599-605. PubMed ID: 18539894
[TBL] [Abstract][Full Text] [Related]
53. 18F-FES PET Has Added Value in Staging and Therapy Decision Making in Patients With Disseminated Lobular Breast Cancer.
Venema C; de Vries E; Glaudemans A; Poppema B; Hospers G; Schröder C
Clin Nucl Med; 2017 Aug; 42(8):612-614. PubMed ID: 28604479
[TBL] [Abstract][Full Text] [Related]
54. Factors influencing the uptake of 18F-fluoroestradiol in patients with estrogen receptor positive breast cancer.
Peterson LM; Kurland BF; Link JM; Schubert EK; Stekhova S; Linden HM; Mankoff DA
Nucl Med Biol; 2011 Oct; 38(7):969-78. PubMed ID: 21982568
[TBL] [Abstract][Full Text] [Related]
55. 16 beta-([18F]fluoro)estrogens: systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors.
VanBrocklin HF; Carlson KE; Katzenellenbogen JA; Welch MJ
J Med Chem; 1993 May; 36(11):1619-29. PubMed ID: 7684451
[TBL] [Abstract][Full Text] [Related]
56. Biodistribution and breast tumor uptake of 16alpha-[18F]-fluoro-17beta-estradiol in rat.
Sasaki M; Fukumura T; Kuwabara Y; Yoshida T; Nakagawa M; Ichiya Y; Masuda K
Ann Nucl Med; 2000 Apr; 14(2):127-30. PubMed ID: 10830531
[TBL] [Abstract][Full Text] [Related]
57.
Peterson LM; Kurland BF; Yan F; Jiresova AN; Gadi VK; Specht JM; Gralow JR; Schubert EK; Link JM; Krohn KA; Eary JF; Mankoff DA; Linden HM
J Nucl Med; 2021 Feb; 62(2):184-190. PubMed ID: 32591490
[TBL] [Abstract][Full Text] [Related]
58. Additional value of 16α-[18F]fluoro-17β-oestradiol PET for differential diagnosis between uterine sarcoma and leiomyoma in patients with positive or equivocal findings on [18F]fluorodeoxyglucose PET.
Yoshida Y; Kiyono Y; Tsujikawa T; Kurokawa T; Okazawa H; Kotsuji F
Eur J Nucl Med Mol Imaging; 2011 Oct; 38(10):1824-31. PubMed ID: 21656049
[TBL] [Abstract][Full Text] [Related]
59. Cross-Species Physiological Assessment of Brain Estrogen Receptor Expression Using
Paquette M; Phoenix S; Lavallée É; Rousseau JA; Guérin B; Turcotte ÉE; Lecomte R
Mol Imaging Biol; 2020 Oct; 22(5):1403-1413. PubMed ID: 32699974
[TBL] [Abstract][Full Text] [Related]
60. Pharmacodynamic imaging guides dosing of a selective estrogen receptor degrader.
Heidari P; Deng F; Esfahani SA; Leece AK; Shoup TM; Vasdev N; Mahmood U
Clin Cancer Res; 2015 Mar; 21(6):1340-7. PubMed ID: 25609068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
